Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
Date:4/30/2008

, but are not limited to, references to the expected timing and planned development activities for ANA598 and ANA773, including the occurrence, timing and pace of future clinical trials, the belief that ANA598 has the potential for beneficial combination with several other anti-HCV agents, the anticipated future clinical benefits of ANA598 and ANA773 and expectations regarding cash utilization. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Conden
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
3. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
4. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
5. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
6. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
11. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Wheaton, Illinois (PRWEB) May 04, 2015 ... treatment options for patients with arm and hand ... rehabilitation exoskeleton at its Oakbrook Terrace network site. ... foundation, the Armeo®Spring is a highly-regarded treatment option ... In acquiring the Armeo®Spring, Marianjoy becomes one of ...
(Date:5/1/2015)... OncoTAb, Inc., a University ... announced that Pinku Mukherjee, Ph.D. has received the ... Governors’ highest faculty honor. Mukherjee received the award, which ... her innovative research and development of cancer diagnostics and ... crowning moment in my scientific career,” said Mukherjee, OncoTAb ...
(Date:5/1/2015)... DIEGO , May 1, 2015 ... company engaged in the development of biosimilar therapeutics ... announced today that its first quarter 2015 financial ... 2015, before the open of market. At 8:30 am ... call to discuss the financial results and provide ...
(Date:5/1/2015)... -- A new report by  visiongain  forecasts ... $22.4bn in 2019. That revenue forecast and others appear ... 2015-2025 ,  published in March 2015. ... forecasts and qualitative analyses of the antithrombotic drugs market. ... London, UK . It produces analyses ...
Breaking Biology Technology:Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5
... police officers and armed forces into Robocops, repelling the force ... nanotechnology however could give those in the line of fire ... , A research paper published in the Institute ... Advanced Materials Technology at the University of Sydney have found ...
... Fla. -- Engineers at Florida State Universitys National High Magnetic ... that could literally shed new light on nanoscience and semiconductor ... Helix -- is operational in 2010, researchers will have the ... not only down the bore, or center, of the magnet, ...
... 31 Amicus Therapeutics,(Nasdaq: FOLD ), ... chaperones for the treatment of human genetic,diseases, ... quarter of 2007.,On a reported basis calculated ... (GAAP), Amicus announced a net loss attributable ...
Cached Biology Technology:Using nanotech to make Robocops 2Let there be light: new magnet design continues magnet lab's tradition of innovation 2Amicus Therapeutics Announces Third Quarter 2007 Financial Results 2Amicus Therapeutics Announces Third Quarter 2007 Financial Results 3Amicus Therapeutics Announces Third Quarter 2007 Financial Results 4Amicus Therapeutics Announces Third Quarter 2007 Financial Results 5Amicus Therapeutics Announces Third Quarter 2007 Financial Results 6Amicus Therapeutics Announces Third Quarter 2007 Financial Results 7Amicus Therapeutics Announces Third Quarter 2007 Financial Results 8
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/8/2015)... CHARLOTTE, N.C. , April 8, 2015 /PRNewswire/ ... technology solutions and services, and Morpho, a leading ... in partnership to produce the market,s most advanced ... Infinisource,s iSolved NXG time clock is setting ... attendance and labor data for the small and ...
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... at the University of Oklahoma Health Sciences Center have found ... of the leading causes of blindness in the United States. ... Diabetes , a publication of the American Diabetes Association. ... blood vessel formation related to eye disease means scientists can ...
... New research out of Wake Forest University School of ... answer for the long-standing question of whether there is ... In a study of more than 1,000 preterm ... association between congenital brain defects and preterm birth, leading ...
... This release is available in German . A ... barrel. Even before the harvest, the grapevines have to overcome all kinds ... to mention the wide variety of pests that can appear on the ... such as mildew, or viruses such as the "Grapevine fanleaf virus" (GFLV ...
Cached Biology News:Brain malformations significantly associated with preterm birth, Wake Forest research shows 2Brain malformations significantly associated with preterm birth, Wake Forest research shows 3Virus-resistant grapevines 2
Human ABCG2 MAb (Clone 5D3)...
... The Beacon 2000 One-Step FP ... characteristic high and low fluorescence polarization ... users of the Beacon 2000 System. ... the polarization values generated by their ...
...
... vitro cell labeling mix, 92.5 ... solution stabilized with 0.1% 2-mercaptoethanol ... 3,4-dicarboxylic acid. *Amino acid mixture ... containing l-[35S]Methionine and l-[35S]Cysteine. * ...
Biology Products: